Efficacy and Safety of Long-Acting β-Agonist/Long-Acting Muscarinic Antagonist Combinations Compare to Long-Acting β-Agonist/Inhaled Corticosteroid Combinations: A Network Meta-Analysis

被引：0
|
作者：
Ahmed, T. Said [1 ]
Al-Sarie, M. [2 ]
Srour, K. [2 ]
Rygielski, S. [3 ]
Ye, F. [2 ]
Hernandez, D. [4 ]
机构：
[1] Univ Toledo, Crit Care Pulm, 2801 W Bancroft St, Toledo, OH 43606 USA
[2] Univ Toledo, Internal Med, 2801 W Bancroft St, Toledo, OH 43606 USA
[3] Univ Toledo, Anesthesia, 2801 W Bancroft St, Toledo, OH 43606 USA
[4] Univ Toledo, Med Ctr, Pulm Crit Care Sleep Med, 2801 W Bancroft St, Toledo, OH 43606 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3045
引用
收藏
页数：2
相关论文
共 50 条
  • [31] COMPARISON OF MONOTHERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST VERSUS COMBINATION THERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST PLUS A LONG-ACTING BETA2-AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Yosuke, Tanaka
    Mitsunori, Hino
    Naomi, Onda
    Hiroyuki, Takoi
    Seiji, Kosaihira
    Norihisa, Motohashi
    Akihiko, Gemma
    RESPIROLOGY, 2014, 19 : 122 - 122
  • [32] Observational Data With Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist May Not Reflect Current Practice With Single Triple Inhalers Response
    Suissa, Samy
    Ernst, Pierre
    CHEST, 2020, 157 (04) : 1045 - 1046
  • [33] COST-EFFECTIVENESS OF FIX-DOSE COMBINATIONS OF LONG-ACTING AGONIST PLUS LONG-ACTING MUSCARINIC ANTAGONIST (LABA/LAMA) FOR THE TREATMENT OF COPD: A SYSTEMATIC REVIEW
    Wang, L.
    Li, H.
    Fu, S.
    Zhang, X.
    Zhang, D.
    Ma, A.
    VALUE IN HEALTH, 2020, 23 : S353 - S353
  • [34] EFFICACY AND SAFETY OF LONG-ACTING BETA AGONISTS plus LONG ACTING MUSCARINIC ANTAGONISTS VS. LONG-ACTING BETA AGONISTS plus INHALED CORTICOSTEROIDS IN COPD: A META-ANALYSIS
    Villalobos, R. E.
    David-Wang, A.
    Magallanes, J.
    RESPIROLOGY, 2016, 21 : 177 - 177
  • [35] Safety of adding long-acting β-agonist therapy
    Reactions Weekly, 2016, 1619 (1) : 10 - 10
  • [36] EFFICACY AND SAFETY OF LONG-ACTING BETA AGONISTS plus LONG ACTING MUSCARINIC ANTAGONISTS VS. LONG-ACTING BETA AGONISTS plus INHALED CORTICOSTEROIDS IN COPD: A META-ANALYSIS
    Villalobos, R. E.
    David-Wang, A.
    Magallanes, J.
    THORAX, 2016, 71 : A113 - A114
  • [37] Bronchoprotective tolerance with inhaled corticosteroid/long-acting β-agonist treatment Reply
    Cardet, Juan Carlos
    Jiang, Xiaofeng
    Lu, Quan
    Gerard, Norma
    McIntire, Kristen
    Boushey, Homer A.
    Castro, Mario
    Chinchilli, Vernon M.
    Codispoti, Christopher D.
    Dyer, Anne-Marie
    Holguin, Fernando
    Kraft, Monica
    Lazarus, Stephen
    Lemanske, Robert F.
    Lugogo, Njira
    Mauger, Dave
    Moore, Wendy C.
    Moy, James
    Ortega, Victor E.
    Peters, Stephen P.
    Smith, Lewis J.
    Solway, Julian
    Sorkness, Christine A.
    Sumino, Kaharu
    Wechsler, Michael E.
    Wenzel, Sally
    Israel, Elliot
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 144 (03) : 873 - 874
  • [38] Compare the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
    Sarac, Pinar
    Sayiner, Abdullah
    TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2016, 64 (02): : 112 - 118
  • [39] Combinations of a long-acting β2 agonist;: is it BI-1744-CL?
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (11) : 1401 - 1404
  • [40] Lifetime Benefits for Budesonide/Glycopyrrolate/Formoterol Fumarate versus Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist and Inhaled Corticosteroid/Long-Acting β2-Agonist Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease
    De Nigris, E.
    Treharne, C.
    Brighton, N.
    Holmgren, U.
    Walker, A.
    Haughney, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
12345